William H. Frey, II,Samuel Scott Panter,Leah Ranae Bresin Hanson
申请号：
US14063125
公开号：
US09216161B2
申请日:
2013.10.25
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of Huntingtons disease. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with Huntingtons disease. The effective amount of DFO is delivered directly to the patients central nervous system for preconditioning, preventing and/or treating Huntingons disease.
